DaVita (NYSE: DVA) was downgraded by equities research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued to investors on Thursday. They currently have a $90.00 price target on the stock.
A number of other analysts have also recently weighed in on DVA. Analysts at Zacks reiterated a “neutral” rating on shares of DaVita in a research note to investors on Wednesday. They now have a $94.00 price target on the stock. Finally, analysts at UBS AG (NYSE: UBS) raised their price target on shares of DaVita to $100.00 in a research note to investors on Saturday, February 18th.
DaVita traded down 1.06% on Thursday, hitting $84.38. DaVita has a 1-year low of $59.14 and a 1-year high of $90.42. The company has a market cap of $7.906 billion and a price-to-earnings ratio of 15.62.
The company last announced its quarterly results on Thursday, February 16th. It reported $1.58 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $1.49 EPS by $0.09. The company’s quarterly revenue was up 13.1% on a year-over-year basis. Analysts expect that DaVita will post $1.61 EPS next quarter.
DaVita Inc. is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, which is an end stage renal disease (ESRD).